BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19773268)

  • 1. Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience.
    Tanaka T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T
    Jpn J Clin Oncol; 2010 Jan; 40(1):73-8. PubMed ID: 19773268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
    Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
    Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
    Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
    Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
    Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis.
    Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Ariga H; Takai Y; Tominaga T
    J Neurosurg Pediatr; 2009 Dec; 4(6):506-14. PubMed ID: 19951035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
    Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
    Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
    Marwaha S; Venner PM; North SA
    Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
    Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
    Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
    Bokemeyer C; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Einhorn L; Nichols CR; Hartmann JT
    Cancer; 2001 Apr; 91(7):1394-401. PubMed ID: 11283942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
    Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
    Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
    Ronnen EA; Kondagunta GV; Bacik J; Marion S; Bajorin DF; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Oct; 23(28):6999-7004. PubMed ID: 16192587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.